Volumetric modulated arc therapy for treatment of solid tumors: current insights

Gabriella Macchia¹
Francesco Deodato¹
Savino Cilla²
Silvia Cammelli³
Alessandra Guido³
Martina Ferioli³
Giambattista Siepe³
Vincenzo Valentini⁴
Alessio Giuseppe Morganti⁵,6,*
Gabriella Ferrandina⁵,6,*

¹Radiation Oncology Unit, ²Medical Physics Unit, “Giovanni Paolo II” Foundation, Catholic University of the Sacred Heart, Campobasso, ³Radiation Oncology Unit, Department of Experimental, Diagnostic and Speciality Medicine, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, ⁴Department of Radiation Oncology, Catholic University of the Sacred Heart, Rome, ⁵Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, ⁶Department of Health Sciences and Medicine, University of Molise, Campobasso, Italy

*These authors contributed equally to this work

Aim: This article discusses the current use of volumetric modulated arc therapy (VMAT) techniques in clinical practice and reviews the available data from clinical outcome studies in different clinical settings. An overview of available literature about clinical outcomes with VMAT stereotactic/radiosurgical treatment is also reported.

Materials and methods: All published manuscripts reporting the use of VMAT in a clinical setting from 2009 to November 2016 were identified. The search was carried out in December 2016 using the National Library of Medicine (PubMed/Medline). The following words were searched: “volumetric arc therapy”[All Fields] OR “vmat”[All Fields] OR “rapidarc”[All Fields], AND “radiotherapy”[All Fields] AND “Clinical Trial”[All Fields].

Results: Overall, 37 studies (21 prospective and 16 retrospective) fulfilling inclusion criteria and thus included in the review evaluated 2,029 patients treated with VMAT; of these patients, ~30.8% had genitourinary (GU) tumors (81% prostate, 19% endometrial), 26.2% head-and-neck cancer (H&NC), 13.9% oligometastases, 11.2% had anorectal cancer, 10.6% thoracic neoplasms (81% breast, 19% lung), and 7.0% brain metastases (BMs). Six different clinical scenarios for VMAT use were identified: 1) BMs, 2) H&NC, 3) thoracic neoplasms, 4) GU cancer, 5) anorectal tumor, and 6) stereotactic body radiation therapy (SBRT) performed by VMAT technique in the oligometastatic patient setting.

Conclusion: The literature addressing the clinical appropriateness of VMAT is scarce. Current literature suggests that VMAT, especially when used as simultaneous integrated boost or SBRT strategy, is an effective safe modality for all cancer types.

Keywords: VMAT, RapidArc, clinical trial, review, radiosurgery, stereotactic, simultaneous integrated boost

Introduction

Since the introduction of intensity-modulated radiotherapy (IMRT) in clinical routine in the late 1990s, a very fast growth has characterized radiotherapy (RT) technology offering newer technologies and techniques to radiation oncologists. Indeed, IMRT,¹ helical tomotherapy,² intensity-modulated arc therapy (IMAT),³ and volumetric modulated arc therapy (VMAT)⁴ enable better radiation dose conformity to the target volume compared to three-dimensional conformal radiotherapy (3D-CRT).

Moreover, these techniques, which underlie various complex computer-based optimization algorithms, allowed the delivery of nonuniform radiation beam intensities in order to obtain highly conformal dose distributions, thus potentially resulting in RT dose escalation to the target with an improved cancer control. Moreover, they allowed the delivery of simultaneous integrated boost (SIB), a technique that permits treating of several volumes safely with different dose prescriptions, thus leading to reduction of the dose to the surrounding radiation-sensitive normal tissues and improvement of the toxicity profile.
In this context, VMAT represents the newest RT technique and can provide additional advantages, such as reduced treatment delivery time compared with conventional static field IMRT. In fact, in VMAT delivery, field shapes, dose rate, and gantry rotation speed can simultaneously vary. These additional degrees of freedom increased the capability of beam intensity modulation with respect to IMAT. Based on Otto’s VMAT algorithm, Varian (Palo Alto, CA, USA) implemented the single-arc form of IMAT and named the system RapidArc®. Elekta (Stockholm, Sweden) and Philips (Amsterdam, the Netherlands) also released their rotational IMRT solutions, named VMAT® and SmartArcTM®, respectively. Since the clinical implementation of these different rotational forms of IMRT by different vendors, the feasibility of applying this novel delivery technique to different cancer sites has been widely explored. Theoretical investigation and a very large number of treatment planning studies have extensively addressed the differences among VMAT, 3D-CRT, IMRT, and helical tomotherapy.1–5

In the last decade, technological improvements in setup, imaging, accuracy in dose delivery, and the ability to compensate for respiratory motion have led to a widespread clinical implementation of stereotactic body radiation therapy (SBRT), also named as stereotactic ablative radiotherapy (SABR). SBRT refers to the delivery of large focused doses over a limited number of fractions to tumor sites, in order to obtain the highest biological effective dose. Because of its rotational nature and its fast delivery timing, VMAT has been immediately recognized as an ideal technique for SBRT that requires steep dose gradients, high precision, and reduction of treatment time, thus minimizing the risk of intrafraction setup deviations or organ motion.6 In this context, a few dosimetric and feasibility studies have confirmed high-dose conformity and fast delivery time in several types of malignancies.7–23

The clinical worldwide use of VMAT is significantly increasing; despite that, the majority of published data are currently confined to planning and feasibility studies.5–15 Results relative to toxicity and clinical outcome are emerging, but still sparse.

This article aims to discuss the current use of VMAT techniques in clinical practice and review the available data from clinical outcome studies in different clinical settings including brain metastases (BMs), head and neck primary neoplasms, thoracic tumors, lower gastrointestinal (GI), and genitourinary (GU) cancers. Moreover, an overview of the available literature about clinical outcomes with VMAT stereotactic/radiosurgical treatment is reported.

Materials and methods
Search strategy
All published manuscripts reporting the use of VMAT in a clinical setting from 2009 (ie, 1 year after VMAT technique implementation) to November 2016 were identified. The search was carried out in December 2016 using the National Library of Medicine (PubMed/Medline). The following words were searched: “volumetric arc therapy”[All Fields] OR “vmat”[All Fields] OR “rapidarc”[All Fields], AND “radiotherapy”[All Fields] AND “Clinical Trial”[All Fields]. In order to identify other possible studies of interest, this process was supplemented by manual examination of reference lists for the available review articles24,25 or clinical trial papers.

Selection criteria
Eligible studies met the following criteria: published paper investigating an adult population with any cancer treated with VMAT, regardless of clinical indication or setting (ie, exclusive, neoadjuvant, adjuvant, and palliative). Additional inclusion criteria were studies, 1) with oncological or toxicity outcomes from VMAT, and 2) published in the English language. Excluded publications were, 1) dosimetric or feasibility studies without clinical data; 2) reviews, editorials, case reports, conference abstracts, and letters to editor; 3) repeated publications by the same institution (ie, analysis was restricted to the most recent or the most comprehensive one); 4) papers reporting comparison between techniques from which it was not possible to extract and separately evaluate the outcome data of 1 arm over the other.

The title, abstract, and keywords of the identified articles were independently analyzed by a pool of researchers (GS, MF, SC, and AG) and disagreement was resolved by 2 supervisors’ opinions (GM and FD); thereafter, papers not suitable for analysis were excluded as mutually agreed.

Potentially eligible studies were retrieved and a full-text evaluation was performed as to whether they satisfied the inclusion and exclusion criteria.

Data collection and analysis
The following data were collected by at least 2 researchers: author’s name and year of publication, study design, clinical setting, number of treated patients, tumor site, VMAT dose, fractionation and technique, image guidance (IG) availability, acute and late toxicity, follow-up time, clinical finding, local control, disease-free survival (DFS), and overall survival (OS). A descriptive analysis was used for the data report. The results are stratified by anatomic site to aid in the interpretation.
Results
According to the search strategy, we were able to identify 116 citations, 97 identified through database searching and 19 identified through other sources (review articles). Based on the title and abstract, 72 publications were excluded because they involved dosimetric issues ($n=62$), or irrelevant topics ($n=10$), leading to 42 full-text articles selected for full inspection. Subsequently, 7 papers were excluded since they reported subset analyses of already selected papers, a case series, and an early halted trial, thus leaving 37 studies (21 prospective and 16 retrospective) fulfilling inclusion criteria and therefore included in the final review (Figure 1).

Overall, these studies evaluated 2,029 patients treated with VMAT; of these patients, ~30.8% had GU tumors (81% prostate, 19% endometrial), 26.2% head-and-neck cancer (H&NC), 13.9% oligometastases, 11.2% anorectal cancer, 10.6% thoracic neoplasms (81% breast, 19% lung), and 7.0% BMs.

Six different clinical scenarios for VMAT use were identified: 1) BMs, 2) H&NC, 3) thoracic neoplasms, 4) GU cancer, 5) anorectal tumor, and 6) SBRT performed by VMAT technique in the oligometastatic patient setting.

For the sake of clarity, we will present and discuss data, site by site.

BM: exclusive, adjuvant, and prophylactic settings
BM are the most common brain tumors in adults and occur in 20%–40% of patients with cancer.14 BMs often cause morbidity and mortality because of effect of the mass or brain site-related symptoms.27-29 The use of a sophisticated technique, such as the VMAT, in this setting is driven by the aim of reducing the irradiation of healthy brain, potentially allowing dose escalation (Table 1).30-33 In this context, 3 studies have investigated the clinical efficacy of VMAT–SIB in different clinical settings including exclusive treatment in the vast majority of cases.30-32 It has to be acknowledged that the VMAT–SIB approaches diverged in terms of total dose, dose per fraction, and timing, thus sustaining a different toxicity profile. In particular, the use of high dose per fraction resulted in higher radionecrosis.32 Overall, the available studies confirmed that BMs can be successfully managed with a satisfying clinical outcome; indeed, despite the heterogeneity of follow-up length as well as clinical end points, the rate of local control was ~80%. In this context, the optimization of the therapeutic window is clinically relevant since the rate of impairment of neurocognitive functions is not negligible and, more importantly, leads to a large amount of social and family sequelae. Prospective assessment of neurocognitive functions before and after hippocampus-sparing whole-brain radiotherapy (WBRT) has shown that adherence to the reference constraints guarantees preservation of neuro-cognitive functions and verbal memory.33 The only caveat remains the deep brain metastases (basal ganglia and thalamus) where the risk of radionecrosis resulted unacceptable at the suggested doses.32

H&NC: exclusive and adjuvant settings
H&NC accounts for 6% of all malignancies, and almost half of patients present with a locally advanced stage due to an
<table>
<thead>
<tr>
<th>Study</th>
<th>Study design</th>
<th>Setting</th>
<th>Number of patients (treated lesions)</th>
<th>Technique, dose (fractionation)</th>
<th>Image guidance</th>
<th>Acute &gt; Grade 3 toxicity</th>
<th>Late &gt; Grade 2 toxicity</th>
<th>Median FUP, months (range)</th>
<th>Clinical outcome</th>
<th>LC rate</th>
<th>OS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weber et al&lt;sup&gt;20&lt;/sup&gt;</td>
<td>P</td>
<td>EXC, ADJ</td>
<td>29</td>
<td>VMAT–SiB 2 arcs, 40 Gy (4) WBR, 30 Gy (3)</td>
<td>CBCT</td>
<td>0%</td>
<td>0%</td>
<td>5.4 (2.6–8.2)</td>
<td>Local failure: 13% Brain failure: 13% Metastases and brain local control: 74%</td>
<td>6 months: 77.9% 6 months: 55.1%</td>
<td></td>
</tr>
<tr>
<td>Awad et al&lt;sup&gt;21&lt;/sup&gt;</td>
<td>R</td>
<td>EXC</td>
<td>30 (73)</td>
<td>VMAT–SiB 2 arcs, 50 Gy, range 20–70.8 (3.3) WBR, 30 Gy, range 28.6–37.5 (2)</td>
<td>na</td>
<td>0%</td>
<td>Radionecrosis: 3%</td>
<td>3.5 (0.03–16.5)</td>
<td>Clinical benefit: 81.5%&lt;sup&gt;a&lt;/sup&gt;</td>
<td>na</td>
<td>Median: 9.4 months</td>
</tr>
<tr>
<td>Nichol et al&lt;sup&gt;22&lt;/sup&gt;</td>
<td>P</td>
<td>EXC</td>
<td>60</td>
<td>VMAT–SiB 2 arcs, Total dose and fractionation 47.5 (9.5) WBR, 20 Gy (4)</td>
<td>Orthogonal kilovoltage imaging Ataxia: 1.7% Radionecrosis: 1.7% Somnolence: 1.7% CTCAE</td>
<td>Nausea: 1.7% Neurophaty: 1.7% Headache: 1.7% Cognitive impairment: 3.3% Ataxia: 5% Motor weakness: 9.9% Radionecrosis: 13.3%</td>
<td>30.5</td>
<td>3 months objective response: 56% 12 months: 88% 36 months: 84%</td>
<td>Median: 10.1 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tsai et al&lt;sup&gt;23&lt;/sup&gt;</td>
<td>P</td>
<td>PRO, EXC, ADJ</td>
<td>24</td>
<td>VMAT (2 full arcs and 2 noncoplanar arcs), PRO: 25 (2.5) ADJ, EXC: 30 (2.5–3)</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>4</td>
<td>Stable neurocognitive functions</td>
<td>na</td>
<td>na</td>
</tr>
</tbody>
</table>

Note: <sup>a</sup>On 27 evaluable lesion.

Abbreviations: P, prospective study; R, retrospective study; EXC, exclusive; ADJ, adjuvant; PRO, prophylactic; VMAT, volumetric modulated arc therapy; SiB, simultaneous integrated boost; WBR, whole-brain radiotherapy; CBCT, cone-beam computed tomography; na, not available; CTCAE, Common Terminology Criteria for Adverse Events scale; FUP, follow-up; LC, local control; OS, overall survival.
The use of VMAT in H&N cancers can be challenging due to the complex anatomy, with tumors often located within close proximity to critical structures (spinal cord, salivary glands, eyes, and dysphagia-related structures) which can limit radiation dose. RT is an important treatment modality in these tumors as it offers an alternative treatment option to surgical resection which can cause unacceptable cosmetic disfigurement and functional impairment.

In the last decade, IMRT has gradually assumed an important role in the management of such diseases because it enables delivery of highly conformal dose distributions and increases the therapeutic ratio as target volumes are often large and concave around nearby critical normal tissues. However, IMRT has several drawbacks such as complexity of treatment planning and delivery requiring extensive quality assurance, prolonged beam delivery time which may worsen the accuracy of treatment because of increased intrafractional patient motion, and reduced patient throughput with subsequent longer waiting lists. Another issue of concern is the increased number of monitor units (MUs) required for IMRT, which could increase the number of secondary malignancies after curative treatment.

In this context, VMAT represents a valid strategy to overcome the above-cited IMRT drawbacks. Indeed, planning studies have reported that VMAT plan quality is at least comparable to standard IMRT, with shorter planning and delivery time, and less MUs. A few retrospective clinical studies have investigated the impact of VMAT in H&N, totaling ~533 patients (Table 2); also in this setting, the dual-arc VMAT technique (Table 2) was the dosimetric treatment of choice. Prophylactic treatment of lymph nodes was performed with doses between 40 and 75 Gy according to different protocols, with fractionation ranging from 1.3 to 1.8 Gy per fraction. The visible disease documented by imaging and/or physical examination received doses up to 75 Gy, with dose fractionation ranging between 2 and 4 Gy. Three of the 6 studies reported the largest series. The impact of VMAT in H&N, totaling ~533 patients (Table 2); also in this setting, the dual-arc VMAT technique (Table 2) was the dosimetric treatment of choice. Prophylactic treatment of lymph nodes was performed with doses between 40 and 75 Gy according to different protocols, with fractionation ranging from 1.3 to 1.8 Gy per fraction. The visible disease documented by imaging and/or physical examination received doses up to 75 Gy, with dose fractionation ranging between 2 and 4 Gy. Three of the 6 studies reported the largest series.

Table 2: VMAT in H&N Cancers

<table>
<thead>
<tr>
<th>Study</th>
<th>Study design</th>
<th>Setting</th>
<th>Number of patients (treated lesions)</th>
<th>Technique, dose (fraction)</th>
<th>Image guidance</th>
<th>Acute ≥ Grade 3 toxicity</th>
<th>Late ≥ Grade 2 toxicity</th>
<th>Median FUP, months (range)</th>
<th>Clinical outcome</th>
<th>LC rate</th>
<th>OS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scorsetti et al&lt;sup&gt;43&lt;/sup&gt;</td>
<td>R</td>
<td>EXC, ADJ</td>
<td>45</td>
<td>VMAT–SIB 1–2 arcs</td>
<td>CBCT</td>
<td>Dysphagia: 7%</td>
<td>Mucositis: 28%</td>
<td>CR: 74%</td>
<td>2–6</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Skin: 14%</td>
<td>CTCAE</td>
<td>PR: 16%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SD: 10%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Doornaert et al&lt;sup&gt;44&lt;/sup&gt;</td>
<td>R</td>
<td>EXC</td>
<td>35</td>
<td>VMAT–SIB 2 arcs</td>
<td>OBI (kV) or CBCT</td>
<td>Laryngeal toxicity: 8%</td>
<td>Moist desquamation: 28.5%</td>
<td>Opioid analgesia: 49%</td>
<td>&lt;6</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Confluent mucositis: 50%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smet et al&lt;sup&gt;45&lt;/sup&gt;</td>
<td>R</td>
<td>EXC ± CT</td>
<td>157</td>
<td>VMAT–SIB 2 arcs</td>
<td>na</td>
<td>VMAT: Mucositis: 49%</td>
<td>Dysphagia: 63%</td>
<td>Skin: 38%</td>
<td>na</td>
<td>VMAT: 17.5</td>
<td>na</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>IMRT: 34.9</td>
<td>4.1–66.9</td>
<td>IMRT: 84.9</td>
<td>70.8%</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Study</th>
<th>Study design</th>
<th>Setting</th>
<th>Number of patients (treated lesions)</th>
<th>Technique, dose (fraction)</th>
<th>Image guidance</th>
<th>Acute ≥ Grade 3 toxicity</th>
<th>Late ≥ Grade 2 toxicity</th>
<th>Median FUP, months (range)</th>
<th>Clinical outcome</th>
<th>LC rate</th>
<th>OS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moncharmont et al&lt;sup&gt;a&lt;/sup&gt;</td>
<td>R</td>
<td>EXC ADJ</td>
<td>150</td>
<td>Prophylactic doses:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>40 or 46.4 or 49.6 Gy</td>
<td>Mucositis: 54%</td>
<td>Dysphagia: 74%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>na</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Versus IMRT; 78 pts</td>
<td></td>
<td>Skin: 36%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Therapeutic doses:</td>
<td>Mucositis: 19%</td>
<td>Dysphagia: 16%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>72 Gy (2.4)</td>
<td></td>
<td>Skin: 16%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Prophylactic doses:</td>
<td>Brachial plexitis: 3%</td>
<td>CTCAE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>40 or 46.4 or 49.6 Gy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>VMAT–SiB 2 arcs&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Therapeutic doses:</td>
<td>Mucositis: 19%</td>
<td>Dysphagia: 16%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>66–70 Gy (2–2.2)</td>
<td></td>
<td>Skin: 16%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Prophylactic doses:</td>
<td>Brachial plexitis: 3%</td>
<td>CTCAE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>50 Gy (2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ozdemir et al&lt;sup&gt;b&lt;/sup&gt;</td>
<td>R</td>
<td>EXC</td>
<td>45</td>
<td>VMAT–SiB 1 arc</td>
<td>kV-CBCT</td>
<td>Dysphagia: 8.9%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>19 pts</td>
<td>Mucositis: 6.7%</td>
<td>Gastrointestinal: 6.6%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>or Dynamic IMRT 18 pts</td>
<td></td>
<td>Hematologic: 2.2%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Therapeutic doses:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>70 Gy (2.1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Prophylactic doses:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>54 Gy (1.6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guo et al&lt;sup&gt;c&lt;/sup&gt;</td>
<td>P</td>
<td>EXC</td>
<td>205</td>
<td>VMAT–SiB 1 arc</td>
<td></td>
<td>Mucositis: 28%</td>
<td>Ear: 18%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Therapeutic doses:</td>
<td>Hematologic (overall): 11%</td>
<td>Xerostomia: 9%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>68–70 Gy (2.0–2.3)</td>
<td>Dry mouth: 10%</td>
<td>Skin: 2%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Prophylactic doses:</td>
<td>Vomiting: 10%</td>
<td>Subcutaneous tissues: 2%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>54–56 Gy (1.8)</td>
<td>Dermatitis: 5%</td>
<td>Mandible: 1%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fever: 1%</td>
<td>Cranial nerve: 1%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Spinal cord: 0.5%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes: <sup>a</sup>122 pts; <sup>b</sup> Any grade late toxicity; <sup>c</sup> Locoregional relapse-free survival.

Abbreviations: VMAT volumetric modulated arc therapy; SiB, simultaneous integrated boost; P, prospective study; R, retrospective study; EXC, exclusive; ADJ, adjuvant; CT, chemotherapy; pts, patients; CBCT, cone-beam computed tomography; OBI (kV), onboard imaging (kilovoltage); na, not available; FUP, follow-up; pts, patients; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; LC, local control; OS, overall survival; CTCAE, Common Terminology Criteria for Adverse Events scale; H&N, head-and-neck; iMRT, intensity-modulated radiotherapy.
reported that clinical response to treatment was encouraging, by Smet et al\textsuperscript{49} who reported survival data favoring VMAT compared to IMRT, and by Guo et al\textsuperscript{48} who reported a 36-month locoregional relapse-free survival of 94% and a 36-month OS of 97.0% (Table 2).

In conclusion, preliminary results in locally advanced H\&NC treated with VMAT showed acceptable or favorable toxicity profile\textsuperscript{48} even using concomitant chemotherapy. Duration of follow-up within the available studies is heterogeneous; moreover, in the only study providing a comparison between the 2 techniques, follow-up duration was shorter in patients managed with VMAT compared to IMRT.\textsuperscript{46} Prospective trials with longer follow-up are needed to achieve reliable conclusions on this matter.

**Thoracic neoplasm: exclusive and adjuvant settings**

A few heterogeneous clinical studies have investigated the use of VMAT in thoracic neoplasm (Table 3);\textsuperscript{49–52} the rationale to use VMAT in this field sounds reasonable since the IMRT quality dose distributions can still be achieved, but in a shorter treatment time that could minimize the impact of intrafraction motion.\textsuperscript{53} Moreover, the convex hull tumor shape makes the delivery of VMAT advantageous and competitive with respect to conventional IMRT in terms of contralateral lung and spinal cord sparing. Concerns still remain regarding the increase of normal tissue volume receiving low-dose radiation in addition to the potential increased risk of secondary malignancy induction especially for breast disease.\textsuperscript{53}

Scorsetti et al\textsuperscript{40} reported acute toxicity, initial outcome results, and therapeutic planning parameters in radiation treatment of advanced lung cancer (Stage III) with volumetric modulated arcs using RapidArc (RA). The earliest published study investigated the clinical outcome of 24 nonsmall cell lung cancer patients treated with VMAT: despite the large target volumes (gross tumor volume: 299±175 cm\textsuperscript{3}, planning target volume: 818±206 cm\textsuperscript{3}) and delivery of curative doses, no severe toxicity was recorded. Moreover, partial response and stabilization of disease were documented in 78% and 22% of cases, respectively, thus highlighting the therapeutic potential of this strategy which nonetheless requires further investigations.\textsuperscript{53}

Another field of application of VMAT in the thoracic area is represented by pleural mesothelioma whose treatment after extrapleural pneumonectomy can include adjuvant irradiation.\textsuperscript{50} Based on the encouraging results obtained with adjuvant IMRT in terms of increased delivered doses and better local control compared to 3D-CRT technique, attention has been focused on the use of VMAT in the same clinical setting because of the possibility of reducing the contralateral lung dose volume receiving ≥5 Gy (V5), or the mean lung dose thus resulting in a lower rate of severe pulmonary toxicity. Indeed, only 1 study has addressed this issue reporting a rate of acute Grade 3 pneumonitis in 20% of patients, a figure that favorably matches with previously reported data on IMRT.\textsuperscript{54,55}

The rationale of VMAT in breast cancer adjuvant treatment concerns a specific subset of patients whose hearts are positioned close to the chest wall and who could not be adequately treated with a modified wide-tangent technique. In dosimetric studies, VMAT plans showed a statistically significant reduction in mean dose to the heart and ipsilateral (left) lung compared with IMRT.\textsuperscript{56} A reduction in the volume of heart and lung receiving low doses (eg, 10 Gy and 5 Gy) may be important in the subgroup of patients who have received anthracycline-based chemotherapy and/or trastuzumab. The mean dose to the full contralateral breast was lower as well.\textsuperscript{56} Scorsetti et al reported the use of the 3-week VMAT–SIB course as adjuvant treatment after breast-conserving surgery,\textsuperscript{57} their Phase II trial showed that the technique is well tolerated and associated with optimal local control.\textsuperscript{52}

To our knowledge, 2 studies analyzed the role of VMAT in the exclusive as well as adjuvant setting.\textsuperscript{51,52} In particular, in the larger prospective series by De Rose et al, VMAT–SIB (40.5 Gy on the whole breast, 48 Gy on surgical bed) provided a very favorable acute and late toxicity profile;\textsuperscript{52} with the limits inherent in the relative short follow-up, an optimal 2-year local control rate was documented.

A different clinical setting was investigated by Kim et al who delivered up to 50 Gy to the whole breast and up to 60–70 Gy on tumor sites.\textsuperscript{51} As far as toxicity is concerned, late Grade ≥2 was registered in only 3.2% of cases.

**GU cancer: exclusive and adjuvant settings**

The increasing incidence of prostate cancer (PC) and endometrial cancer (EC), as well as the favorable rate of curability and long survival, justifies the strenuous pursuit of healthy tissue toxicity reduction policy.

Indeed, treatment of pelvic lymph nodes as well as the primary tumor or tumor bed is indicated in high-risk PC and EC patients by international guidelines [www.NCCN.org]. The so-called horseshoe shape of the lymph node target, which includes the small intestine and rectum in its concavity, represents a condition particularly suitable to benefit from the intensity-modulated techniques and especially from VMAT.
Table 3 VMAT in thoracic neoplasms

<table>
<thead>
<tr>
<th>Study</th>
<th>Tumor site</th>
<th>Study design</th>
<th>Setting</th>
<th>Number of patients</th>
<th>Technique, dose (fractionation)</th>
<th>Image guidance</th>
<th>Acute toxicity, Grade ≥3</th>
<th>Late toxicity, Grade ≥2</th>
<th>Median FUP, months (range)</th>
<th>Clinical outcome</th>
<th>LC rate</th>
<th>DFS</th>
<th>OS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scorsetti et al</td>
<td>Lung (NSCLC)</td>
<td>P</td>
<td>EXC</td>
<td>24</td>
<td>VMAT 2 partial arcs 66 Gy (2) in 22 pts; 60 Gy (2) in 1 pt; 50 Gy (2) for 1 pt</td>
<td>CBCT 0%</td>
<td>RTOG na</td>
<td>RTOG na</td>
<td>6</td>
<td>3 months PR &gt;50%: 56%</td>
<td>3 months PR &lt;50%: 22%</td>
<td>3 months SD: 22%</td>
<td>na</td>
</tr>
<tr>
<td>Kimura et al</td>
<td>Mesothelioma</td>
<td>P</td>
<td>ADJ</td>
<td>17</td>
<td>VMAT–SiB 3 arcs 54 Gy (1.8)</td>
<td>na</td>
<td>Pneumonitis: 20% na</td>
<td>RTOG na</td>
<td>11</td>
<td>na</td>
<td>12 months: 12 months: 12 months:</td>
<td>na</td>
<td>55.7%</td>
</tr>
<tr>
<td>Kim et al</td>
<td>Breast</td>
<td>R</td>
<td>EXC</td>
<td>31</td>
<td>VMAT–SiB 3 arcs Whole breast: 50 Gy (2) Macrocopscopic disease: 60–70 Gy (2.4–2.8) followed by 10 Gy electron boost</td>
<td>na 0%</td>
<td>Pneumonitis: 3.2% 25.2%</td>
<td>RTOG RTOG na</td>
<td>24 months: 2 months: na</td>
<td>na</td>
<td>99.3%</td>
<td>99.3%</td>
<td></td>
</tr>
<tr>
<td>De Rose et al</td>
<td>Breast</td>
<td>P</td>
<td>ADJ</td>
<td>144</td>
<td>VMAT–SiB 2 partial arcs Whole breast: 40.5 Gy (2.7)</td>
<td>CBCT/2D–2D matching</td>
<td>Skin: 1.4% RTOG CTCAE</td>
<td>CTCAE na</td>
<td>37 (24–55)</td>
<td>na</td>
<td>24 months: 2 months: na</td>
<td>na</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: NSCLC, nonsmall cell lung cancer; P, prospective study; R, retrospective study; EXC, exclusive; ADJ, adjuvant; VMAT, volumetric modulated arc therapy; SiB, simultaneous integrated boost; pts, patients; CBCT, cone-beam computed tomography; FUP, follow-up; PR, partial remission; SD, stable disease; na, not available; LC, local control; DFS, disease-free survival; OS, overall survival; RTOG, Radiation Therapy Oncology Group scale; CTCAE, Common Terminology Criteria for Adverse Events scale.
Concerning PC, dosimetric studies demonstrated a comparable or higher sparing to organs at risk (OARs) obtained with VMAT in comparison with the IMRT plans, especially by dual-arc technique that can obtain a superior conformity and homogeneity compared with single-arc plans.\(^ {58-60}\) In addition, the better efficiency of VMAT delivery reduces the treatment time, making it an attractive solution for radiation oncologists.\(^ {58-60}\)

Eight clinical studies (5 prospective and 3 retrospective) have been reviewed in this study,\(^ {61-68}\) PC represents the disease on which VMAT has been employed since the beginning and most frequently.

Five studies addressed only exclusive setting,\(^ {62,64-67}\) while the remaining studies investigated adjuvant setting\(^ {63}\) or both.\(^ {61,68}\) Most of the patients enrolled in these studies (including series between 23 and 113 patients) were treated mostly by VMAT–SIB dual-arc and triple-arc techniques, almost all using IG as kilovoltage (kV) or cone-beam computed tomography (CBCT). It is important to mention the importance of IG during RT, for example, with CBCT. This enables patient positioning errors to be followed and corrected with high precision. In PC, where internal organ movement is a key point for patient positioning and target localization, IG permits the safe delivery of higher doses per fraction. Pesce et al and Sveistrup et al treated only prostate volume, thus using single-arc technique up to 78 Gy/2 Gy fraction;\(^ {61,65}\) both authors reported that IG-VMAT is a safe treatment for PC, with few and mild changes in urinary and GI symptoms after 1 year from RT completion. Sexual symptoms deteriorated during and after RT; however, Pesce et al\(^ {61}\) reported preservation of erectile function in 44% of patients, while Sveistrup et al\(^ {65}\) stressed the issue that the use of hormonal therapy was associated with worse sexual symptoms. However, prostatic antigen decreased to values close to zero at the end of the treatment, thus leading consideration of clinical outcome as encouraging. No data on local control or OS are available.

To date, the study by Sveistrup et al\(^ {63}\) is the one with the most comprehensive analysis of the symptoms before, during, and after the RT; however, the limitation of this work is the use of a questionnaire (Prostate Cancer Symptom Scale – PCSS scale) which makes it difficult to compare data with other experiences.

Pelvic lymph nodes, prostate, and seminal vesicles were treated by 5 authors,\(^ {62,64-66,68}\) using a single- to triple-arc technique, with doses ranging from 46.8 Gy for nodal coverage to 78 Gy for prostate irradiation. Almost all used IG as kV or CBCT, and ~335 patients were treated from 2012 to 2016. The conclusions were that VMAT–SIB is technically feasible and safe providing high target coverage and OAR sparing with acceptable GI and GU toxicity. Hegazy et al reported that ~50% of patients (low and intermediate risk) with partial potency prior to RT retained functional potency on long-term follow-up (median 16 months; range: 14–32).\(^ {67}\)

Moreover, Hesselberg et al\(^ {68}\) confirmed a favorable acute toxicity profile also in the case of treatment of large pelvic lymph node volumes with optimal dose coverage. Finally, Ng et al\(^ {64}\) paid attention to a not trivial issue: as the population ages, the number of patients presenting with hip prostheses is expected to increase, and treatment planning for patients with metallic prosthesis composed of high Z materials posed challenges. In fact, hip prosthesis determines streaking and blurring artifacts in the CT data set which prevents accurate contour delineation and alters the image density values and moreover implies dose calculation uncertainties.\(^ {70,71}\) In this context, Ng et al\(^ {64}\) outlined that VMAT provides an elegant solution to deliver dose-escalated RT in patients with unilateral and bilateral hip replacements with minimal acute and late toxicities. Only Hegazy et al reported outcome data reporting 2- and 3-year biochemical recurrence-free survival of 90% and 72%, respectively; the 3- and 4-year OS rates were 88% and 72%, respectively (Table 4).\(^ {67}\)

More recently, clinical data on EC have been reported by Alonzi et al\(^ {72}\) and Macchia et al\(^ {73}\) in 2 Phase I–II studies enrolling patients treated on pelvic lymph nodes and boosted on the vaginal cuff by VMAT–SIB dual-arc techniques. The 2-year local control rates were 98.5% and 100% in the 2 studies, with OS rates ranging from 94% and 96% (Table 4). Both authors concluded that VMAT is feasible and well tolerated in terms of acute as well as late toxicities. Indeed, while recognizing that vaginal brachytherapy represents the standard technique for vaginal vault irradiation (less dose to OAR, no organ motion, reduction of linear accelerator overload, and treatment time), the authors stated that VMAT–SIB not only represents a valid option in the case of lack of vaginal brachytherapy, but can be used in special conditions like unfavorable anatomy or patient refusal and/or claustrophobia.\(^ {72,73}\) However, prolonged follow-up is needed to evaluate other clinical results including late toxicity and local control and survival. Additional issues such as secondary malignancy induction should also be examined, given the paucity of data relative to this type of risk for IMRT and VMAT techniques.

**Anorectal cancer: exclusive and neoadjuvant settings**

Exclusive or neoadjuvant concomitant chemoradiation is presently considered as the standard treatment option for
<table>
<thead>
<tr>
<th>Study</th>
<th>Tumor site</th>
<th>Study design</th>
<th>Setting</th>
<th>Number of patients</th>
<th>Technique, dose (fractionation)</th>
<th>Image guidance</th>
<th>Acute toxicity Grade ≥3</th>
<th>Late toxicity Grade ≥2</th>
<th>Median FUP, months (range)</th>
<th>LC rate</th>
<th>DFS</th>
<th>OS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pesce et al</td>
<td>Prostate</td>
<td>EXC, ADJ</td>
<td>P</td>
<td>45</td>
<td>VMAT 1 arc 76–78 (2)</td>
<td>CBCT</td>
<td>0</td>
<td>CTCAE</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td>Alongi et al</td>
<td>Prostate</td>
<td>R</td>
<td>EXC</td>
<td>70</td>
<td>VMAT–SiB 2 arcs Prostate: 71.4–74.2 (2.55–2.65) Seminal vesicles: 61.6–65.5 (2.2–2.3) Pelvic lymph nodes: 51.8 (1.85)</td>
<td>na</td>
<td>GU: 1%</td>
<td>na</td>
<td>11 (3.5–23)</td>
<td>na</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td>Alongi et al</td>
<td>Prostate</td>
<td>P</td>
<td>ADJ</td>
<td>39</td>
<td>VMAT–SiB 1 or 2 arcs 70–71.4 (2.5–2.55)</td>
<td>CBCT</td>
<td>0</td>
<td>RTOG</td>
<td>22.8 (9–28)</td>
<td>na</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td>Ng et al</td>
<td>Prostate</td>
<td>R</td>
<td>EXC</td>
<td>23</td>
<td>VMAT–SiB 1–2 arcs Prostate: 72 (2.25) Seminal vesicles: 64 (2) Pelvic lymph nodes: 50 (1.56)</td>
<td>kv</td>
<td>0</td>
<td>RTOG</td>
<td>40.9 (30–54)</td>
<td>na</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td>Sveistrup et al</td>
<td>Prostate</td>
<td>P</td>
<td>EXC</td>
<td>87</td>
<td>VMAT 1 arc 78 (2) Implant markers and kv</td>
<td>CBCT</td>
<td>0%</td>
<td>CTCAE</td>
<td>12</td>
<td>na</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td>Ishii et al</td>
<td>Prostate</td>
<td>P</td>
<td>EXC</td>
<td>100</td>
<td>Two sequential treatments: VMAT–SiB 2 arcs Pelvic lymph nodes: 46.8 (1.8) Prostate: 52 (2) followed by VMAT 1 arc Prostate: 26 (2)</td>
<td>Implant markers and kv</td>
<td>0%</td>
<td>CTCAE</td>
<td>≤3</td>
<td>na</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td>Hegazy et al</td>
<td>Prostate</td>
<td>P</td>
<td>EXC</td>
<td>29</td>
<td>VMAT–SiB 2 arcs PTv1: 70 (2.5) PTv2: 56 (2) PTv3: 50.4 (1.8)</td>
<td>CBCT</td>
<td>GI: 0%</td>
<td>GU: 0%</td>
<td>42 (18–72)</td>
<td>na</td>
<td>24 months</td>
<td>36 months</td>
</tr>
<tr>
<td>Hesselberg et al</td>
<td>Prostate</td>
<td>R</td>
<td>EXC, ADJ</td>
<td>113</td>
<td>VMAT–SiB 2–3 arcs EXC: 74–78 (2) ADJ: 50.4–66 (1.8–2) Filming based on bony anatomy (daily); kv (once a week)</td>
<td>Filming based on bony anatomy (daily); kv (once a week)</td>
<td>GI: 0%</td>
<td>GU: 0%</td>
<td>14</td>
<td>na</td>
<td>36 months</td>
<td>48 months</td>
</tr>
</tbody>
</table>
patients with anorectal cancer, providing consistent rates of locoregional control (LC), sphincter preservation, and OS. The acute toxicity profile linked to this approach, especially if a multidrug regimen is coupled to chemoradiation, refers particularly to skin, GI, and GU OARs and may potentially hinder the dose escalation to tumor volume, or stop treatment for a prolonged period, thereby reducing the radiobiological effectiveness of therapy.\textsuperscript{12,74} Seven clinical studies from 2010 to 2016 reported data on rectal or anal cancers treated by VMAT (Table 5).\textsuperscript{75–81} The rationale, also in this setting, is closely related to the higher OAR sparing, dose escalation possibility, and faster delivery compared to 3D-CRT or IMRT.

In particular, in the neoadjuvant setting of rectal cancer (RC), 3 studies accounting for 124 patients were included.\textsuperscript{75–77} Two of them, 1 prospective and 1 retrospective, compared VMAT technique to 3D-CRT with conventional doses (45/1.8 or 50.4/1.8 Gy).\textsuperscript{75,76} Richetti et al\textsuperscript{75} prospectively treated 25 RC patients by single arc, while Dröge et al\textsuperscript{76} retrospectively studied ~81 patients treated by a dual-arc technique; both authors concluded that VMAT improves conformity and reduces treatment times, with similar treatment outcomes.\textsuperscript{75,76} Moreover, in the larger study,\textsuperscript{76} a reduction of the high-grade acute and late toxicities was documented. On the other hand, in a Phase II study with concurrent multidrug chemotherapy (oxaliplatin plus capecitabine), Picardi et al\textsuperscript{77} first used the VMAT–SIB strategy to escalate doses on macroscopic disease up to 57.5 Gy (2.3 Gy/fraction), while delivering 45 Gy (1.8 Gy/fraction) to pelvic lymph nodes. The authors reported an excellent pathologic response rate (pT0-Tmic: 61.1%) with quite encouraging outcomes also in terms of local control, DFS, and OS (Table 5). However, despite the use of the VMAT technique, ~44% of patients had a non-negligible acute toxicity, hence they concluded that the implementation of IMRT and VMAT in RC is attractive and potentially facilitates dose escalation, but increases the risk of developing acute proctitis because the rectum inevitably receives high doses; therefore, the use of this scheme can be justified in clinical practice only in patients with advanced disease.

On the other hand, in the exclusive setting of anal cancer, 4 chemoradiation studies (1 Phase I and 3 retrospective ones accounting for 103 patients) were analyzed.\textsuperscript{78–81} One of them\textsuperscript{80} investigated the irradiation of a single volume with either 2 full arcs or 4 half-arc VMAT technique and 6 MV photon energies. The delivered dose of 50.4 Gy at 1.8 per fraction caused mostly severe skin toxicity (29.4%), with low GI (11.8%) and GU (5.9%) severe toxicity. These figures are lower than the ones reported in 3D-CRT studies, for example,
<table>
<thead>
<tr>
<th>Study</th>
<th>Tumor site</th>
<th>Study design</th>
<th>Setting</th>
<th>Number of patients</th>
<th>Technique, dose (fractionation)</th>
<th>Image guidance</th>
<th>Acute toxicity Grade ≥3</th>
<th>Late toxicity Grade ≥2</th>
<th>Median FUP, months (range)</th>
<th>Clinical outcome</th>
<th>LC rate</th>
<th>DFS</th>
<th>OS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richetti et al (9)</td>
<td>Rectum</td>
<td>NA CRT</td>
<td>25&lt;sup&gt;a&lt;/sup&gt;</td>
<td>VMAT 1 arc: 44 (2.0) or 45 (1.8)</td>
<td>na</td>
<td>GI: 8% CTCAE</td>
<td>na</td>
<td>na</td>
<td>Downstaging (at surgery); VMAT vs 3D-CRT: T 41% vs 26% --N 12% vs 21% Upstaging (at surgery): T 6% vs 11%--N 18% vs 11%--M 6% vs 0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dröge et al (10)</td>
<td>Rectum</td>
<td>R NA CRT</td>
<td>81&lt;sup&gt;b&lt;/sup&gt;</td>
<td>VMAT 2 arcs: 50.4 (1.8)</td>
<td>na</td>
<td>GU: 1%; GI: 3% CTCAE</td>
<td>na</td>
<td>na</td>
<td>18.3 (4.0–59.2)</td>
<td>R0 resection: 90%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Picardi et al (11)</td>
<td>Rectum</td>
<td>NA CRT</td>
<td>18&lt;sup&gt;c&lt;/sup&gt;</td>
<td>VMAT–SiB 2 arcs: MVPI Nodal drainage: 45 (1.8) Disease: 57.5 (2.3)</td>
<td>na</td>
<td>GI: 27.8% GU: 5.6% CTCAE; Leukopenia: 5.6% Skin: 5.6% CTCAE</td>
<td>na</td>
<td>na</td>
<td>61 (3–70)</td>
<td>PR: 72.2% 12 months; CR: 22.2% 100% 12 months; OR: 94.4% 36 months; 5.6% 68.6% 36 months; 63.8% 60 months; 60 months; 60 months; 5.6%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tozzi et al (14)</td>
<td>Anus</td>
<td>eXC CRT</td>
<td>36&lt;sup&gt;d&lt;/sup&gt;</td>
<td>VMAT–SiB 2–4 arcs: Macroscopic disease: 59.4 (1.8); elective lymph nodes: 49.5 (1.5)</td>
<td>kv</td>
<td>GI: 8.3% Skin: 13.9% CTCAE</td>
<td>na</td>
<td>na</td>
<td>19 (7–59)</td>
<td>CR: 83.3% 60 months; PR: 2% 78.1% 85.7%</td>
<td>actuarial survival: 52.8 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leon et al (15)</td>
<td>Anus</td>
<td>eXC CRT</td>
<td>11&lt;sup&gt;e&lt;/sup&gt;</td>
<td>VMAT/IMRT–SiB Macroscopic disease: 57.5 (2.13); clinical lymph nodes: 54 (2.0); elective lymph nodes: 48.6 (1.8)</td>
<td>na</td>
<td>GI: 36% HE: 54% Skin: 63% CTCAE</td>
<td>na</td>
<td>na</td>
<td>22 (12–27)</td>
<td>CR: 91% 3 months; TR: 73%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weber et al (16)</td>
<td>Anus</td>
<td>eXC CRT</td>
<td>17&lt;sup&gt;f&lt;/sup&gt;</td>
<td>VMAT 2–4 arcs: 50.4 (1.8)</td>
<td>na</td>
<td>Skin: 29.4% GI: 11.8% GU: 5.9% Leukopenia: 11.8% Anemia: 5.9% Thrombocytopenia: 5.9% CTCAE</td>
<td>na</td>
<td>na</td>
<td>15.3 (3.3–54)</td>
<td>12 months: 100% 24 months: 100% 24 months: 100%</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> CRT: combined-modality treatment protocol (surgery ± chemoradiation therapy).

<sup>b</sup> CRT: phase II/III study.

<sup>c</sup> CRT: single-centre experience.

<sup>d</sup> CRT: labelling for toxicity according to RTOG 0235/0316.

<sup>e</sup> CRT: phase I/II study.

<sup>f</sup> CRT: single-centre experience.
in Radiation Therapy Oncology Group 98-11 trial that reported a crude rate of acute Grade 3/Grade 4 toxicities of 48% for the skin and 35% for GI.82 One of the major issues that should be clarified for VMAT is whether single or multiple arcs should be applied to realize proper treatments. In our review, 3 studies employed a dual-arc SIB approach78–81 delivering a different daily dose to selected treatment volumes during the same treatment fraction. According to dosimetric results by Clivio et al,12 the double arcs can slightly improve the sparing of OAR guaranteeing more flexibility in dose modulation compared to single-arc treatments.

In 3 studies,78–80 elective lymph nodes received doses between 45 and 49.5 Gy (1.5 Gy/fraction); clinically detectable lymph nodes were treated with doses from 50.4 to 54 Gy (1.8–2 Gy/fraction), and macroscopic anal disease received doses from 50.4 to 59.4 Gy (1.8 Gy/fraction). Noteworthy, the SIB approach was able to shorten the overall treatment time with a consequent potential benefit on treatment outcomes.

The study reporting the most frequent toxicity was that by Leon et al79 who documented the rates of skin and GI toxicity in 63% and 36% of cases respectively, figures closer to 3D-CRT values than IMRT/VMAT.82 Besides the limits of the sample size (N=11), it is conceivable that these results may be ascribed to the higher total dose and, more probably, to the highest dose per fraction (2.13 Gy) plus the addition of cetuximab that may have contributed to induce severe dermatitis given its peculiar skin toxicity properties. None of the other studies reported similar results, hence they cannot be justified given the poor clinical outcome (Table 5).

In conclusion, the available studies provided further lines of evidence supporting the implementation and use of VMAT–SIB on a routine basis for the treatment of cancer of the anal canal in combination with concurrent CT due to lower rates of acute organ toxicity and promising trends in LC and DFS.

SBRT–VMAT (exclusive setting)

In the “oligo-metastatic” setting, local approach may improve the outcome by keeping the burden of disease below the lethal threshold. However, most patients are unfit for surgery because of unfavorable tumor factors or poor general conditions. For these patients, a broad variety of alternative local therapeutic approaches are available besides conventional radiochemotherapy approaches. SBRT is a high-precision technique with tight planning margins and a sophisticated treatment plan allowing rapid dose fall-off away from the treatment area. It provides improved volume targeting and smaller irradiated volumes of normal tissue. On the other
In conclusion, the possibility to easily integrate SBRT–VMAT in the context of a systemic treatment due to intrinsic low toxicity and fast administration makes this approach very attractive. From a practical point of view, the introduction of VMAT for SBRT has resulted in a marked reduction of treatment time (especially by FFF beams technology), less toxicity and subsequently in a better quality of life. The FFF technology has been applied in Scorsetti et al; similar findings were reported by Filippi et al who represents the only experience with stereotactic radiosurgery, these results are not presented in Scorsetti et al studies because it was not possible to retrieve the data about intrafraction uncertainties, costs related to highly complex management of SBRT from the whole series.

Table 6 because it was not possible to retrieve the data about intrafraction uncertainties, costs related to highly complex management of SBRT from the whole series.

Table 6: Stereotactic body radiation therapy (SBRT)–VMAT

<table>
<thead>
<tr>
<th>Study</th>
<th>Tumor site</th>
<th>Study design</th>
<th>Setting</th>
<th>Technique, dose (fractionation)</th>
<th>Image guidance</th>
<th>Acute toxicity Grade ≥ 3</th>
<th>Late toxicity Grade ≥ 2</th>
<th>Median FUP, months (range)</th>
<th>Clinical outcome</th>
<th>LC rate</th>
<th>DFS</th>
<th>OS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scorsetti et al</td>
<td>Abdominal lesions</td>
<td>R</td>
<td>EXC</td>
<td>SBRT–VMAT 45–75 Gy / 12–26 Gy</td>
<td>CBCT</td>
<td>0% CTCAE</td>
<td>0%</td>
<td>12 (6–22)</td>
<td>79.2%</td>
<td>na</td>
<td>na</td>
<td></td>
</tr>
<tr>
<td>Deodato et al</td>
<td>Various</td>
<td>P</td>
<td>EXC</td>
<td>SBRT–VMAT 75 Gy (25)–67.5 Gy in 8% of lesions, 60 Gy in 5%, 52.5 Gy in 5%</td>
<td>CBCT</td>
<td>1.6% (chronic chest wall pain)</td>
<td>na</td>
<td>12 (2–26)</td>
<td>94.7%</td>
<td>na</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scorsetti et al</td>
<td>Liver</td>
<td>P</td>
<td>EXC</td>
<td>SBRT–VMAT 45–75 Gy / 12–26 Gy</td>
<td>CBCT</td>
<td>0% CTCAE</td>
<td>0%</td>
<td>12 (8–20)</td>
<td>85%</td>
<td>24 months:</td>
<td>na</td>
<td>88%</td>
</tr>
<tr>
<td>Deodato et al</td>
<td>Various</td>
<td>P</td>
<td>EXC</td>
<td>SRS–VMAT 12–28 Gy / 12–28 Gy</td>
<td>na</td>
<td>0% CTCAE</td>
<td>na</td>
<td>11 (1–38)</td>
<td>ORR + SD by morphological 72%</td>
<td>24 months:</td>
<td>na</td>
<td>71.8%</td>
</tr>
</tbody>
</table>
Discussion and conclusion

Few papers in literature evaluated systematically the clinical efficacy of VMAT technique in cancer treatment. In 2011, Teoh et al. reviewed the current literature and clinical use in practice of VMAT treatment in various tumor sites, including prostate, lower GI, gynecological and head and neck, thoracic, central nervous system, and breast. Obviously, due to the time frame, the study was extremely complete about dosimetric issues, while reporting few clinical data about clinical outcome. A recent paper by Infusino et al. has been published, mainly focusing attention on the clinical utility of RapidArc™ technology. This is the first clinical review about VMAT technique regardless of the manufacturing company, waiting for the setup of randomized clinical trials focused on this issue, VMAT can be considered a valid alternative option.

Based on the data collected in this review, PC treatment with VMAT has received the greatest support in the current literature, followed by anorectal cancer. In these settings, patients received mostly VMAT–SIB, thus being able to benefit from the SIB strategy that allows increasing of dose per fraction to the boost volume, keeping the elective volume dose at a lower level, and providing clinical and dosimetric advantages.

We identified few clinical scenarios for VMAT treatments, and we were able to estimate local control and toxicity for all indications, albeit with the aforementioned limits for all indications, including the context of retrospective single institutional studies and inherent biases associated with them. The majority of patients were prospective (N = 21) reflecting the growing interest of the issue. However, published series of outcomes and toxicity are available, and 17 out of 37 studies did not report any data on late toxicity, probably because of the short follow-up time on late toxicity.

The use of VMAT in radiation oncology has increased over the years, and its role on clinical outcome is still being explored. Indeed, over a 7-year span, only 37 studies reported clinical results in terms of outcomes and toxicity. Interestingly, the majority of papers were prospective (N = 21) reflecting the growing interest of the issue. However, published series of outcomes and toxicity are available, and 17 out of 37 studies did not report any data on late toxicity, probably because of the short follow-up time on late toxicity.

In addition, toxicity could have been underestimated since relative data were captured retrospectively. We identified 6 major clinical scenarios for VMAT treatments and were able to estimate local control and toxicity for all indications, albeit with the aforementioned limits for all indications, including the context of retrospective single institutional studies and inherent biases associated with them. The majority of patients were prospective (N = 21) reflecting the growing interest of the issue. However, published series of outcomes and toxicity are available, and 17 out of 37 studies did not report any data on late toxicity, probably because of the short follow-up time on late toxicity.

The majority of studies report an excellent OAR sparing compared to IMRT; waiting for the setup of randomized clinical trials on this issue, VMAT can be considered a valid alternative option.

Based on the data collected in this review, PC treatment with VMAT has received the greatest support in the current literature, followed by anorectal cancer. In these settings, patients received mostly VMAT–SIB, thus being able to benefit from the SIB strategy that allows increasing of dose per fraction to the boost volume, keeping the elective volume dose at a lower level, and providing clinical and dosimetric advantages.

### Table 1: Treatment of thoracic node metastases

<table>
<thead>
<tr>
<th>Author</th>
<th>Tumor Site</th>
<th>Treatment</th>
<th>MOD</th>
<th>Dose (Gy)</th>
<th>Pts</th>
<th>Median</th>
<th>CTCAE</th>
<th>ORR</th>
<th>CR</th>
<th>PR</th>
<th>SD</th>
<th>PD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scorsetti et al.</td>
<td>Prostate</td>
<td>PC</td>
<td>EXC</td>
<td>72</td>
<td>14.5 (6–23)</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Franceschini et al.</td>
<td>Thoracic node</td>
<td>R</td>
<td>EXC</td>
<td>29 (32)</td>
<td>12 (2–35)</td>
<td>CR: 14 pts</td>
<td>na</td>
<td>Median: 9 months</td>
<td>28%</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Abbreviations:
P, prospective study; R, retrospective study; EXC, exclusive; SBRT, stereotactic body radiotherapy; VMAT, volumetric modulated arc therapy; FFF, flattening filter-free; CBCT, cone-beam CT; CR, complete remission; PR, partial remission; SD, stable disease; SRS, stereotactic radiosurgery; PD, progressive disease; pts, patients; CTCAE, Common Terminology Criteria for Adverse Events; GI, gastrointestinal; GU, genitourinary; FUP, follow-up; ORR, overall response rate; LC, local control; DFS, disease-free survival; OS, overall survival.

### Notes:

1. In 3–6 fractions.
2. Calculated on 33 patients.
3. Median dose 18 Gy.
For all series, the therapeutic results appear encouraging, especially when large volumes need to be irradiated, and dual-arc SIB strategy is used,\textsuperscript{77} or high-sensitive structure sparing is required.\textsuperscript{32}

In conclusion, the literature addressing the clinical appropriateness of VMAT is scarce. Current literature suggests that VMAT, especially when used as SIB or SBRT strategy, is an effective safe modality for all cancer types. Prospective studies with systematic data collection are needed for further understanding of the VMAT role in daily clinical use.

Disclosure
The authors report no conflicts of interest in this work.

References


